Investment strategy

Fund+ invests in and supports:

innovative companies

  • active in life sciences (primary focus on therapeutics, not excluding diagnostics and medical devices), with a strong patient-centric approach addressing unmet medical needs
  • in an advanced development stage (first round and subsequent financing)
  • with an experienced management team respecting highest ethical values
  • presenting a solid business plan
  • invest in Europe, with a focus on Belgium

Fund+ aims to become a significant minority shareholder (more than 10%) and offers access to a wide international network within the scientific, academic and financial community. The intended investment size per project will be between EUR 5 million and EUR 15 million.

Fund+ plays a constructive role as board member in our portfolio companies.

Fund+ wants to become a long term partner of companies, create value for its shareholders and generate and formally evaluate a tangible beneficial societal impact.

 

The societal impact will be evaluated by using a proprietary SRI scorecard that is based on the SRI policy that you can find here.